MARKETS / NYSE / CNMD

NYSE · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP

Conmed Corp. CNMD

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$1.4B

▲ 5.2% YoY

Net income

$47.1M

▼ 64.5% YoY

Free cash flow

$150.9M

▼ 2.0% YoY

In brief

What this company does

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. As of December 31, 2025, it had approximately 3,900 full-time employees, including approximately 2,400 in operations and the remaining in sales, marketing, research and development and administration. Its headquarters are located in Largo, Florida. Its product lines consist of orthopedic surgery, which accounted for 42% of net sales in 2025, and general surgery, which accounted for 58%. In orthopedic surgery, it designs, manufactures and globally distributes products that enable orthopedic surgeons to surgically address sports medicine injuries in the knee, hip, shoulder and lower extremities. Its general surgery product line offers products in the areas of advanced surgical and advanced endoscopic technologies. CONMED Corporation was incorporated under the laws of the State of New York in 1970 and became a Delaware corporation in May 2020.

Written from the business description in CONMED CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 17 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.4B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 1.4 · Net income 0.0

Compound annual growth

Revenue

+9.6%

+9.8%

+6.7%

+4.5%

Net income

+37.7%

+4.4%

+3.0%

EPS, diluted

+36.4%

+3.3%

+2.5%

Dividend / share

−9.1%

−5.6%

−2.8%

Returned to shareholders

+1.1%

+1.6%

+1.1%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +9.8% a year over five years — but profit grew faster: net income at +37.7%, earnings per share at +36.4%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

3 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 7.5% · Net 3.4%

ROE

FY2025 · ROE 4.7%

Gross margin54.6%

Operating margin7.5%

Net margin3.4%

Return on assets2.0%

EBITDAUSD 119.8M

Each USD of equity produced 5 cents of profit this year.

Cash & shareholders

USD 24.7M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 150.9

Net buybacks $M Dividends $M

FY2025 · Dividends 24.7 · Net buybacks —

Dividends paidUSD 24.7M

Net buybacks—

Share of profit52.6%

Consecutive raises—

USD 24.7M in dividends — 53% of the year's profit went back to shareholders.

Total assetsUSD 2.3B

EquityUSD 1.0B

CashUSD 40.8M

Gross debtUSD 834.2M

Net debtUSD 793.4M

Current ratio2.14×

Net debt stands at 77% of equity.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	1.4	1.3	1.2	1.0	1.0	0.9	1.0	0.9	0.8	0.8	0.7	0.7	0.8	0.8	0.7	0.7	0.7
Operating income $B	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.0
EBITDA $B	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0
Income tax $B	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	−0.0	0.0	0.0	0.0	0.0	0.0	−0.0	0.0	0.0
Net income $B	0.0	0.1	0.1	−0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free cash flow $B	0.2	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0
EPS, diluted $	1.51	4.25	2.04	−2.68	1.94	0.32	0.97	1.41	1.97	0.52	1.09	1.16	1.28	1.41	0.03	1.05	0.42
Dividend / sh $	0.60	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.80	0.65	0.60	0.00	0.00	·
Payout %	53	19	38	−30	37	240	79	55	40	151	72	68	46	32	0	0	·
ROE %	4.7	14.7	8.2	−10.5	8.4	1.3	4.2	6.3	9.2	2.5	5.2	5.4	5.9	6.9	0.1	5.2	2.1

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 83 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 12 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityElectromedical & Electrotherapeutic Apparatus

Listed onNYSE

Incorporated inDelaware

Fiscal year endsDecember 31

Data on record since2009